Valuation: Gilead Sciences, Inc.

Market Cap 167B 146B 134B 124B 234B 16,055B 239B 1,607B 632B 7,863B 626B 612B 27,069B P/E 2026 *
-48.4x
P/E 2027 * 17x
Enterprise Value 176B 154B 142B 131B 247B 16,966B 252B 1,698B 668B 8,309B 662B 647B 28,605B EV / Sales 2026 *
5.78x
EV / Sales 2027 * 5.15x
Free-Float
99.88%
Yield 2026 *
2.42%
Yield 2027 * 2.5%
1 day-1.48%
1 week+3.43%
Current month+6.28%
1 month+8.50%
3 months-2.44%
6 months+7.50%
Current year+9.40%
1 week 129.4
Extreme 129.405
140.61
1 month 123
Extreme 123
140.61
Current year 116.88
Extreme 116.88
157.29
1 year 107.75
Extreme 107.75
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Chief Financial Officer

-3,000 0.0002%
7/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
7/1/26 Sell

Chief Executive Officer

-15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-1.48%+3.43%+24.08%+70.06% 167B
+0.85%-0.80%+52.79%+159.97% 1,051B
+1.23%-1.53%+54.58%+59.41% 609B
+0.04%+2.58%+34.47%+84.84% 450B
-0.09%+0.94%+30.59%+21.91% 330B
-0.82%-0.55%+35.34%+36.23% 284B
-0.20%-0.41%+22.73%+17.41% 263B
+0.69%+2.44%-19.13%-39.81% 223B
-1.42%+0.80%+24.27%+57.85% 198B
-0.36%+3.64%+2.37%-31.26% 143B
Average -0.33%+0.85%+26.21%+43.66% 371.78B
Weighted average by Cap. -0.19%+0.16%+36.37%+73.80%

Financials

2026 *2027 *
Net sales 30.47B 26.63B 24.57B 22.65B 42.69B 2,934B 43.63B 294B 116B 1,437B 114B 112B 4,947B 32.4B 28.31B 26.13B 24.08B 45.39B 3,120B 46.4B 312B 123B 1,528B 122B 119B 5,260B
Net income -3.39B -2.96B -2.73B -2.52B -4.75B -327B -4.86B -32.68B -12.86B -160B -12.73B -12.46B -551B 9.76B 8.53B 7.87B 7.26B 13.68B 940B 13.98B 94.09B 37.01B 460B 36.66B 35.86B 1,585B
Net Debt 9.46B 8.27B 7.63B 7.03B 13.25B 911B 13.55B 91.18B 35.86B 446B 35.53B 34.75B 1,536B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-17 $134.28 -1.48% 6,903,235
26-07-16 $136.30 +3.49% 7,926,819
26-07-15 $131.70 +1.28% 4,467,637
26-07-14 $130.04 -1.04% 5,255,960
26-07-13 $131.40 +1.21% 5,131,594
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
134.28USD
Average target price
158.30USD
Spread / Average Target
+17.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock